Modern approaches in therapy of combined hormonedependent gynaecological pathology with the use of GnRH agonists in women of reproductive and perimenopausal age

The purpose of our research was to estimate the eff ectiveness of the modern methods of therapy
of a combined hormone-dependent gynaecological pathology (leiomyoma, genital endometriosis,
recurrent hyperplasia of the endometrium, infertility) with the use of Gn RH agonists in women of
reproductive and perimenopausal age; and to study of the infl uence of organ-preserving methods
of treatment on reproductive function and prophylaxis of the perimenopausal period pathology.
To achieve this purpose, we analyzed the results of treatment of 22 patients, aged 28 to 53 years
(mean age – 45,1 ± 3,4 years) with combined hormone-dependent gynaecological pathology (infertility,
leiomyoma and adenomyosis – 3; leiomyoma in conjunction with endometrial hyperplasia – 9;
leiomyoma in combination with adenomyosis and endometrial hyperplasia – 5, genital endometriosis
and endometrial hyperplasia – 4) with the use of Gn RH agonist Luprid depot. Luprid depot was
administered intramuscularly once in a month in a dose of 3,75 mg for 3–6 months, depending on
the morphological structure of the endometrium and myometrium.
We found that Luprid Depot is an eff ective medicine for complex conservative treatment of
combined hormone-dependent gynecological pathology, as it reduces the severity of clinical symptoms
of endometriosis and leiomyoma, infl uence tumor size and the size of the uterus, delays the
need of operation, allows to avoid radical surgery and restores fertility. To achieve longlasting therapeutic
eff ects it is advisable to prolong treatment of combined hormone-dependent gynecological
pathology up to 9 months.